|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT03047681 |
|
Date of registration:
|
08/02/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement
TAVR |
|
Scientific title:
|
Tryptase Levels as a Marker of Mast Cell Activity and the Prognostic Implication in Patients Post Transcatheter Aortic Valve Replacement |
|
Date of first enrolment:
|
February 2017 |
|
Target sample size:
|
30 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT03047681 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
Zach Rozenbaum, MD |
|
Address:
|
|
|
Telephone:
|
972-3-6973313 |
|
Email:
|
zachr@tlvmc.gov.il |
|
Affiliation:
|
|
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- 18 years of age and older
- Capable of giving informed consent
- Undergoing TAVR
Exclusion Criteria:
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Transcatheter Aortic Valve Implantation Prosnosis and Complications
|
|
Intervention(s)
|
|
Diagnostic Test: venous blood withdrawl
|
|
Primary Outcome(s)
|
|
Mortality
[Time Frame: 1 year]
|
|
Secondary Outcome(s)
|
|
Complications
[Time Frame: 30 days]
|
|
Mortality
[Time Frame: 7 and 30 days]
|
|
Secondary ID(s)
|
|
0678-15-TLV
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|